Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Other Non-Current Assets (2016 - 2019)

Ascendis Pharma A's Other Non-Current Assets history spans 4 years, with the latest figure at $1.6 million for Q4 2019.

  • For Q4 2019, Other Non-Current Assets rose 22.52% year-over-year to $1.6 million; the TTM value through Dec 2019 reached $1.6 million, up 22.52%, while the annual FY2019 figure was $1.6 million, 23.96% up from the prior year.
  • Other Non-Current Assets for Q4 2019 was $1.6 million at Ascendis Pharma A, up from $1.3 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.6 million in Q4 2019 and bottomed at $74178.2 in Q4 2017.
  • The 4-year median for Other Non-Current Assets is $805551.6 (2016), against an average of $826164.5.
  • The largest annual shift saw Other Non-Current Assets plummeted 74.37% in 2017 before it soared 1681.84% in 2018.
  • A 4-year view of Other Non-Current Assets shows it stood at $289366.1 in 2016, then tumbled by 74.37% to $74178.2 in 2017, then skyrocketed by 1681.84% to $1.3 million in 2018, then increased by 22.52% to $1.6 million in 2019.
  • Per Business Quant, the three most recent readings for ASND's Other Non-Current Assets are $1.6 million (Q4 2019), $1.3 million (Q4 2018), and $74178.2 (Q4 2017).